Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19
Foster City, Calif., July 8, 2020 – Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences: “Since the beginning of the COVID-19 pandemic, Gilead has mobilized its deep expertise in virology to rapidly assess the potent investigational antiviral, remdesivir, to evaluate its safety and efficacy as a potential…
